Your browser doesn't support javascript.
loading
Case report: JC polyomavirus nephropathy in simultaneous heart-kidney transplantation: the role of viral-specific in situ hybridization staining.
Abu Jawdeh, Bassam G; Smith, Maxwell L; Hudson, Madeline R; Mour, Girish K; Budhiraja, Pooja; Rosenthal, Julie L.
Afiliação
  • Abu Jawdeh BG; Division of Nephrology, Mayo Clinic Arizona, Phoenix, AZ, United States.
  • Smith ML; Division of Anatomic Pathology, Mayo Clinic Arizona, Phoenix, AZ, United States.
  • Hudson MR; Department of Pharmacy, Mayo Clinic Arizona, Phoenix, AZ, United States.
  • Mour GK; Division of Nephrology, Mayo Clinic Arizona, Phoenix, AZ, United States.
  • Budhiraja P; Division of Nephrology, Mayo Clinic Arizona, Phoenix, AZ, United States.
  • Rosenthal JL; Division of Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ, United States.
Front Med (Lausanne) ; 10: 1282827, 2023.
Article em En | MEDLINE | ID: mdl-37928458
ABSTRACT

Introduction:

JC polyomavirus (JCPyV) is a ubiquitous virus that can be latent in the brain and the kidney. It is the etiologic agent responsible for progressive multifocal leukoencephalopathy, a fatal, demyelinating disease of the central nervous system, and rarely causes polyomavirus nephropathy in immunocompromised kidney transplant recipients. Case description We present the first case of JCPyV nephropathy in a simultaneous heart-kidney transplant patient, where viral-specific in situ hybridization staining of the kidney tissue was utilized to confirm the diagnosis. The patient was diagnosed 6 years after simultaneous heart-kidney transplantation and was treated with immunosuppression reduction and intravenous immunoglobulin.

Discussion:

JCPyV nephropathy should be considered in the differential diagnosis of kidney allograft injury, particularly, with suggestive light microscopy histologic features in the absence of BK polyomavirus viremia and/or viruria. In addition to obtaining JCPyV PCR in the blood, in situ hybridization staining may have a utility in confirming the diagnosis. To date, we lack effective JCPyV-specific therapies, and prompt initiation of immunosuppression reduction remains the mainstay of treatment.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article